Risk of dyslipidemia and major adverse cardiac events with tofacitinib versus adalimumab in rheumatoid arthritis: a real-world cohort study from 7580 patients

• Hoofdauteurs: Xiao-Na Ma (Auteur), Mei-Feng Shi (Auteur), Shiow-Ing Wang (Auteur), Wei Feng (Auteur), Shu-Lin Chen (Auteur), Xiao-Qin Zhong (Auteur), Qing-Ping Liu (Auteur), James Cheng-Chung Wei (Auteur), Chang-Song Lin (Auteur), Qiang Xu (Auteur)
• Formaat: Boek
• Gepubliceerd in: Frontiers Media S.A., 2024-05-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

ObjectiveTo compare the effects of tofacitinib and adalimumab on the risk of adverse lipidaemia outcomes in patients with newly diagnosed rheumatoid arthritis (RA).MethodsData of adult patients newly diagnosed with RA who were treated with tofacitinib or adalimumab at least twice during a 3-year per...